CN1215045C - 3,3－二苯基丙胺类化合物的新衍生物的稳定盐 - Google Patents

3,3－二苯基丙胺类化合物的新衍生物的稳定盐 Download PDF

Info

Publication number
CN1215045C
CN1215045C CNB008157057A CN00815705A CN1215045C CN 1215045 C CN1215045 C CN 1215045C CN B008157057 A CNB008157057 A CN B008157057A CN 00815705 A CN00815705 A CN 00815705A CN 1215045 C CN1215045 C CN 1215045C
Authority
CN
China
Prior art keywords
acid
phenyl
formula
oxygen base
carbonyl oxygen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB008157057A
Other languages
English (en)
Chinese (zh)
Other versions
CN1390194A (zh
Inventor
C·麦斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Pharma GmbH
Original Assignee
Schwarz Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7929277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1215045(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schwarz Pharma AG filed Critical Schwarz Pharma AG
Publication of CN1390194A publication Critical patent/CN1390194A/zh
Application granted granted Critical
Publication of CN1215045C publication Critical patent/CN1215045C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C219/28—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
  • Luminescent Compositions (AREA)
  • Detergent Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB008157057A 1999-11-16 2000-11-15 3,3－二苯基丙胺类化合物的新衍生物的稳定盐 Expired - Lifetime CN1215045C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19955190A DE19955190A1 (de) 1999-11-16 1999-11-16 Stabile Salze neuartiger Derivate von 3,3-Diphenylpropylaminen
DE19955190.1 1999-11-16

Publications (2)

Publication Number Publication Date
CN1390194A CN1390194A (zh) 2003-01-08
CN1215045C true CN1215045C (zh) 2005-08-17

Family

ID=7929277

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008157057A Expired - Lifetime CN1215045C (zh) 1999-11-16 2000-11-15 3,3－二苯基丙胺类化合物的新衍生物的稳定盐

Country Status (30)

Country Link
US (1) US6858650B1 (enExample)
EP (3) EP1481964B1 (enExample)
JP (6) JP4083431B2 (enExample)
KR (2) KR100536095B1 (enExample)
CN (1) CN1215045C (enExample)
AT (3) ATE395056T1 (enExample)
AU (1) AU778132B2 (enExample)
BR (1) BRPI0015610C1 (enExample)
CA (1) CA2389749C (enExample)
CY (2) CY1106204T1 (enExample)
CZ (2) CZ302497B6 (enExample)
DE (5) DE29923134U1 (enExample)
DK (3) DK1690536T3 (enExample)
EA (1) EA005588B1 (enExample)
ES (3) ES2236032T7 (enExample)
GE (1) GEP20084430B (enExample)
HK (1) HK1045148B (enExample)
HU (2) HU227608B1 (enExample)
IL (2) IL149567A0 (enExample)
IS (2) IS2124B (enExample)
MX (1) MXPA02004603A (enExample)
NO (2) NO323920B1 (enExample)
NZ (1) NZ519230A (enExample)
PL (1) PL201422B1 (enExample)
PT (3) PT1690536E (enExample)
SI (3) SI1230209T1 (enExample)
SK (3) SK287430B6 (enExample)
UA (2) UA73324C2 (enExample)
WO (1) WO2001035957A1 (enExample)
ZA (1) ZA200203315B (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
DE29923134U1 (de) * 1999-11-16 2000-06-29 Schwarz Pharma Ag, 40789 Monheim Stabile Salze neuartiger Derviate von 3,3-Diphenylpropylaminen
DE10028443C1 (de) * 2000-06-14 2002-05-29 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von 3,3-Diarylpropylaminen, (R,S)- und (R)-4-Phenyl-2-chromanon-6-carbonsäure sowie (R)-4-Phenyl-2-chromanon-carbonsäure-cinchonidinsalz und deren Verwendung zur Herstellung eines rechtsdrehenden Hydroxybenzylalkohols und von pharmazeutischen Zusammensetzungen
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
DE10315878B4 (de) * 2003-04-08 2009-06-04 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Fesoterodin und Verwendung
WO2005012227A2 (en) * 2003-08-05 2005-02-10 Ranbaxy Laboratories Limited Process for preparation of 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenol, a metabolite of tolterodine
ES2235648B1 (es) * 2003-12-22 2006-11-01 Ragactives, S.L. Procedimiento para la obtencion de tolterodina.
US8034823B2 (en) 2005-02-22 2011-10-11 Savvipharm Inc Method of increasing drug oral bioavailability and compositions of less toxic orotate salts
KR100647068B1 (ko) 2005-09-15 2006-11-23 하나제약 주식회사 라세믹ｎ,ｎ-디이소프로필-3-(2-히드록시-5-메틸페닐)-3-페닐프로판아민의 제조방법
US8067594B2 (en) * 2006-05-24 2011-11-29 Pfizer Inc. Process for the production of benzopyran-2-ol derivatives
EP1862449A1 (en) * 2006-05-31 2007-12-05 Schwarz Pharma Ltd. A shortened synthesis of substituted hydroxymethyl phenols
EP1940774B1 (en) * 2006-05-31 2014-03-05 Schwarz Pharma Ltd. New synthesis of substituted hydroxymethyl phenols
IES20060424A2 (en) * 2006-06-08 2007-10-31 Schwarz Pharma Ltd Accelerated synthesis of (3-Diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)phenol and its phenolic monoesters
US7807715B2 (en) 2006-06-09 2010-10-05 Ucb Pharma Gmbh Pharmaceutical compositions comprising fesoterodine
PE20080331A1 (es) * 2006-06-09 2008-06-19 Sanol Arznei Schwarz Gmbh Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
ATE477234T1 (de) 2006-06-09 2010-08-15 Schwarz Pharma Ltd Synthese von phenolischen estern von hydroxymethylphenolen
BRPI0712842A2 (pt) * 2006-06-12 2012-07-24 Sanol Arznei Schwarz Gmbh internediÁrio quiral, processo para produÇço do mesmo e seu emprego na fabricaÇço da tolterodina, fesoterodina ou o metabàlito ativo das mesmas.
IES20060435A2 (en) 2006-06-12 2007-12-12 Schwarz Pharma Ltd Shortened synthesis using paraformaldehyde or trioxane
WO2009037569A2 (en) * 2007-09-21 2009-03-26 Actavis Group Ptc Ehf An improved process for the preparation of fesoterodine
US20100297241A1 (en) * 2007-10-01 2010-11-25 Actavis Group Ptc Ehf Amorphous Fesoterodine Fumarate
EP2294047A2 (en) * 2008-04-04 2011-03-16 Actavis Group PTC EHF Novel mandelate salt of fesoterodine
EP2323967A2 (en) * 2008-07-21 2011-05-25 Actavis Group PTC EHF Fesoterodine comprising a reduced amount of dehydroxyfesoterodine
IT1392082B1 (it) * 2008-12-10 2012-02-09 Chemi Spa Nuove forme solide della fesoterodina fumarato
MX2011011937A (es) 2009-05-11 2012-01-27 Ratiopharm Gmbh Desfesoterodina en la forma de una sal del acido tartarico.
IT1394219B1 (it) * 2009-05-15 2012-06-01 Chemi Spa Metodo di preparazione di fesoterodina fumarato di elevata purezza.
IT1394217B1 (it) * 2009-05-15 2012-06-01 Chemi Spa Metodo di preparazione di fesoterodina e/o fesoterodina fumarato.
US20120220655A1 (en) 2009-09-03 2012-08-30 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Crystalline forms of fesoterodine fumarate and fesoterodine base
IT1396373B1 (it) * 2009-10-29 2012-11-19 Dipharma Francis Srl Procedimento per la preparazione di fesoterodina.
EP2316432A1 (de) 2009-10-30 2011-05-04 ratiopharm GmbH Zusammensetzung enthaltend Fesoterodin und Ballaststoffe
US20110124903A1 (en) * 2009-11-20 2011-05-26 Actavis Group Ptc Ehf Solid state forms of fesoterodine intermediates
IT1397521B1 (it) * 2009-12-21 2013-01-16 Dipharma Francis Srl Procedimento per la preparazione di fesoterodina con un basso contenuto di impurezze.
IT1397920B1 (it) * 2010-02-08 2013-02-04 Dipharma Francis Srl Forma cristallina di fesoterodina fumarato e procedimento per la sua preparazione
EP2549985A1 (en) 2010-03-22 2013-01-30 Cadila Healthcare Limited Stable pharmaceutical compositions comprising fesoterodine
US8748433B2 (en) 2010-04-30 2014-06-10 Merck Sharp & Dohme Corp. β3 adrenergic receptor agonists
WO2011141932A2 (en) 2010-05-11 2011-11-17 Intas Pharmaceuticals Limited Process for preparation of phenolic monoesters of hydroxymethyl phenols
WO2011145019A1 (en) * 2010-05-17 2011-11-24 Orchid Chemicals And Pharmaceuticals Limited Improved process for diphenylpropylamine derivatives
IT1401451B1 (it) 2010-06-10 2013-07-26 Chemi Spa Nuovo processo di preparazione di 2-idrossi-4-fenil-3,4-diidro-2h-cromen-6-il-metanolo e (r)-2-[3-(diisopropilammino)-1-fenilpropil]-4-(idrossimetil)fenolo.
WO2011158257A1 (en) 2010-06-18 2011-12-22 Panacea Biotec Ltd Preparation process of fesoterodine and intermediates
WO2012025941A2 (en) 2010-08-25 2012-03-01 Cadila Healthcare Limited Processes for the preparation of fesoterodine
IT1403094B1 (it) * 2010-12-09 2013-10-04 Dipharma Francis Srl Procedimento per la preparazione di fesoterodina o un suo sale
WO2012098560A2 (en) * 2011-01-17 2012-07-26 Msn Laboratories Limited Process for the preparation of muscarinic receptor antagonist
TWI520732B (zh) 2011-01-18 2016-02-11 輝瑞有限公司 固體分子分散液
EP2508173A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Stabilized pharmaceutical composition comprising fesoterodine
EP2508175A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof
US9422228B2 (en) 2012-05-04 2016-08-23 Crystal Pharma, S.A.U. Process for the preparation of optically pure fesoterodine derivatives
ITMI20121232A1 (it) 2012-07-16 2014-01-17 Cambrex Profarmaco Milano Srl Procedimento per la preparazione di 2-(3-n,n-diisopropilamino-1-fenilpropil)-4-idrossimetil-fenolo e suoi derivati
TR201721437A2 (tr) 2017-12-25 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Fesoterodi̇ni̇n modi̇fi̇ye salim sağlayan formülasyonlari
CN116472262A (zh) * 2020-10-27 2023-07-21 威娜德国有限责任公司 化妆品级品质的2-甲氧基甲基-对苯二胺

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ198953A (en) * 1980-11-14 1984-10-19 Lilly Co Eli (-)-n-methyl-3-(2-methylphenoxy)-3-phenylpropylamine,its salts and pharmaceutical formulations
IL66831A0 (en) * 1981-10-05 1982-12-31 Kefalas As Indane derivatives
SE8800207D0 (sv) * 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
EP0445749B1 (en) * 1990-03-08 1996-07-10 Fujisawa Pharmaceutical Co., Ltd. N-Monosubstituted cyclopentenylamines, a process for their preparation and their use as medicaments
JPH0483431A (ja) * 1990-07-26 1992-03-17 Seiko Epson Corp 選択呼出受信機
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
SE9701144D0 (sv) * 1997-03-27 1997-03-27 Pharmacia & Upjohn Ab Novel compounds, their use and preparation
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
DE29923134U1 (de) * 1999-11-16 2000-06-29 Schwarz Pharma Ag, 40789 Monheim Stabile Salze neuartiger Derviate von 3,3-Diphenylpropylaminen

Also Published As

Publication number Publication date
DK1230209T3 (da) 2005-05-30
KR100536095B1 (ko) 2005-12-12
JP2003514018A (ja) 2003-04-15
EA005588B1 (ru) 2005-04-28
JP2011148824A (ja) 2011-08-04
DE50009239D1 (de) 2005-02-17
DE50013365D1 (de) 2006-10-05
EP1481964B1 (de) 2006-08-23
JP2010180243A (ja) 2010-08-19
CY1106204T1 (el) 2011-06-08
ES2270240T3 (es) 2007-04-01
NO323920B1 (no) 2007-07-23
PL356766A1 (en) 2004-07-12
PT1230209E (pt) 2005-05-31
EP1690536B1 (de) 2008-05-14
IS8382A (is) 2006-03-29
WO2001035957A1 (de) 2001-05-25
SK288384B6 (sk) 2016-08-01
UA73324C2 (uk) 2005-07-15
MXPA02004603A (es) 2004-09-10
BR0015610A (pt) 2002-07-30
PT1690536E (pt) 2008-07-14
SI1481964T1 (sl) 2006-12-31
CA2389749C (en) 2009-03-31
EP1230209B3 (de) 2011-10-05
ATE395056T1 (de) 2008-05-15
CN1390194A (zh) 2003-01-08
HUP0204034A3 (en) 2004-12-28
JP2010180242A (ja) 2010-08-19
EA200200511A1 (ru) 2002-10-31
AU2666701A (en) 2001-05-30
SK288185B6 (sk) 2014-04-02
ZA200203315B (en) 2003-09-23
SI1690536T1 (sl) 2008-08-31
IS6351A (is) 2002-04-19
HUP0204034A2 (hu) 2003-03-28
DE19955190A1 (de) 2001-06-21
CZ20021343A3 (cs) 2002-09-11
WO2001035957A8 (de) 2001-06-21
DE50015163D1 (de) 2008-06-26
IS2673B (is) 2010-09-15
IL149567A0 (en) 2002-11-10
HU228197B1 (en) 2013-01-28
JP5503393B2 (ja) 2014-05-28
HK1045148A1 (en) 2002-11-15
US6858650B1 (en) 2005-02-22
JP5290351B2 (ja) 2013-09-18
DE29923134U1 (de) 2000-06-29
CY1110389T1 (el) 2015-04-29
EP1230209B1 (de) 2005-01-12
EP1481964A1 (de) 2004-12-01
CA2389749A1 (en) 2001-05-25
UA77322C2 (en) 2006-11-15
KR20050100711A (ko) 2005-10-19
ATE337293T1 (de) 2006-09-15
JP4083431B2 (ja) 2008-04-30
BR0015610B8 (pt) 2017-10-31
BRPI0015610B1 (pt) 2016-04-19
CZ302967B6 (cs) 2012-01-25
NZ519230A (en) 2004-11-26
HK1067114A1 (en) 2005-04-01
SI1230209T1 (en) 2005-06-30
JP2014111589A (ja) 2014-06-19
IS2124B (is) 2006-07-14
HU227608B1 (en) 2011-09-28
DK1690536T3 (da) 2008-09-01
WO2001035957A3 (de) 2001-12-27
DK1481964T3 (da) 2006-11-27
KR20020059744A (ko) 2002-07-13
AU778132B2 (en) 2004-11-18
EP1230209A2 (de) 2002-08-14
HU0900587D0 (en) 2009-11-30
IL149567A (en) 2007-08-19
HK1095736A1 (en) 2007-05-18
NO20065380L (no) 2002-05-15
EP1690536A3 (de) 2006-08-23
PT1481964E (pt) 2006-12-29
SK6572002A3 (en) 2002-12-03
GEP20084430B (enExample) 2008-07-25
HK1045148B (zh) 2005-05-06
HUP0900587A3 (en) 2010-04-28
JP5650924B2 (ja) 2015-01-07
BRPI0015610C1 (pt) 2021-05-25
PL201422B1 (pl) 2009-04-30
KR100563149B1 (ko) 2006-03-21
ES2236032T3 (es) 2005-07-16
JP5717824B2 (ja) 2015-05-13
EP1690536A2 (de) 2006-08-16
ES2236032T7 (es) 2012-06-14
ATE286872T1 (de) 2005-01-15
NO20022314D0 (no) 2002-05-15
NO332637B1 (no) 2012-11-26
NO20022314L (no) 2002-05-15
ES2303708T3 (es) 2008-08-16
SK287430B6 (sk) 2010-09-07
JP2007137895A (ja) 2007-06-07
CZ302497B6 (cs) 2011-06-15

Similar Documents

Publication Publication Date Title
CN1215045C (zh) 3,3－二苯基丙胺类化合物的新衍生物的稳定盐
CN1305839C (zh) 苯基甘氨酸衍生物
CN1305853C (zh) Hmg辅酶a还原酶抑制剂的制备方法
CN1183118C (zh) 4-烷氧基-环己烷-1-氨基-羧酸酯及其生产方法
CN1072661C (zh) 新的取代[2－(1－哌嗪基)乙氧基]甲基化合物
CN1091636A (zh) 药物
CN1617854A (zh) 苯基(烷基)羧酸衍生物和二酸苯基烷基杂环衍生物及其用作具有血清葡萄糖和/或血清脂降低活性的药物的应用
CN1191230C (zh) 神经氨酸苷酶抑制剂ro－64－0796的制备方法
CN1723192A (zh) 作为药剂的亚芳基－羧酸(2－氨基－苯基)－酰胺衍生物
CN1105990A (zh) 苯基链烷醇胺衍生物
HK1040390B (zh) 可被取代的对羟基扁桃酸类化合物的制备方法
CN1960965A (zh) 氨基－烷氧基－庚酸烷基酯的合成
CN1407967A (zh) 立体选择性地合成环状氨基酸的方法
CN1030584A (zh) 新型的噻吩衍生物及其制备方法
CN1190421C (zh) 环状化合物的生产方法
CN1194960C (zh) 4,5－二氨基莽草酸衍生物的制备方法
CN1538954A (zh) 用于合成埃坡霉素及其衍生物并经保护的3,5-二羟基-2,2-二甲基-戊腈及其制备方法和应用
CN1867546A (zh) 新颖化合物及其在药物中的用途、其制备方法以及含有它们的药物组合物
CN1759097A (zh) 制备用以获得n－甲酰基羟胺的中间体的化学方法
CN1741985A (zh) 钙细胞溶解酶化合物
CN88102858A (zh) 可用作抗高血压剂的肼衍生物的制备方法
HK1049999A1 (en) Imidazole derivatives
CN1252049A (zh) 2－取代的苯甲酰基－环烷基－1－羧酸衍生物
CN1538952A (zh) 用于合成埃坡霉素及其衍生物并经保护的3,5-二羟基-2,2-二甲基-戊酰胺及其制备方法和应用
CN1103761C (zh) 制备1－取代－乙内酰脲的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20050817

CX01 Expiry of patent term